Skip to content
Head to head

Aquestive Therapeutics vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: AQST · TAK

Updated 6 minutes ago

1-year performance, rebased to 100

AQST -20.3%TAK +28.0%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (70); Takeda Pharmaceutical has done best over the past year (+29%); Takeda Pharmaceutical pays the highest dividend yield.
AQSTTAK
Snapshot
Sector----
Last price4.6218.37
Change today+0.22%+1.49%
1-year return-22.6%+29.2%
Market cap$579.86M$58.68B
52-week range2.93 – 7.5512.77 – 19.10
Valuation
P/E (TTM)-7.00-55.67
P/E percentile, own 5-yr range32nd4th
P/B-10.241.23
Dividend yield0.00%3.26%
Profitability & growth
EPS (TTM)-0.78-0.31
Net profit (TTM)$-97.90M$-977.54M
Revenue (TTM)$54.09M$4.62T
Revenue growth (YoY)+38.1%+10.2%
Gross margin67.0%65.5%
Operating margin-97.5%10.4%
Net margin-144.6%-3.5%
Free cash flow (TTM)$-45.95M$626.68B
Ownership & sentiment
Institutional ownership58.3%51.5%
Insider activity (12mo)25 buy / 24 sell22 buy / 28 sell
Short interest (% of float)21.6%0.1%
Analyst consensus100% buy (3)100% buy (1)
Analyst price target$9 (+88%)$43 (+134%)
StockVane view
StockVane Quant RatingC (55)C (70)
Company
Employees14747,029
Founded20041781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.